Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs

Acromegaly is a condition most commonly diagnosed in the fifth decade of life and has numerous treatment options. In this regard, Mycapssa<sup>®</sup> is the first FDA-approved oral octreotide capsule for treating acromegaly, combining the efficacy of the somatostatin receptor ligand, oc...

Full description

Bibliographic Details
Main Authors: Charles P. Daniel, Maxwell J. Wagner, Grant E. Borne, Connor J. Plaisance, Shahab Ahmadzadeh, Alfonso Aquino, Sahar Shekoohi, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pathophysiology
Subjects:
acromegaly
Mycapssa<sup>®</sup> (oral octreatide)
somatostatin analogs
growth hormone
IGF-1
Online Access:https://www.mdpi.com/1873-149X/30/3/29

Similar Items

Similar Items